Releases

News

Releases

19. August, 2021

Second quarter report Q2-2021 – planning for the pivotal trials

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Releases

29. June, 2021

Cessatech announces new Chairman of the Board – getting ready for the pivotal studies

  The Board of Directors has appointed Adam Steensberg as new Chairman of the...

Read more

Releases

31. May, 2021

Last subject dosed in bioavailability trial 0204 of lead product candidate

Clinical trial 0204 in 12 healthy volunteers investigating the absolute bioavailability of CT001, reports...

Read more

Releases

14. May, 2021

Cessatech A/S is awarded IPO of the year 2020 by independent editorial Affärsvärlden

Among the 26 micro-companies, the IPO guide’s reviewers found an average of 2.9 flags....

Read more

Releases

19. April, 2021

First quarter report Q1-2021 – ‘one down, two to go’ of the major milestones of 2021

Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1...

Read more

Media

26. March, 2021

Cessatech utvecklar nästa generations smärtlindring för barn

Cessatech är ett danskt läkemedelsbolag specialiserat på forskning och utveckling av smärtstillande nässpray som...

Read more

Releases

24. March, 2021

Cessatech reports first subject dosed in bioavailability trial of lead product candidate

Clinical trial 0204 in healthy volunteers will investigate the absolute bioavailability of CT001. Primary...

Read more

Releases

9. March, 2021

Cessatech A/S is awarded Best Medical Treatment IPO Nordics in 2020 by independent editorial

CFI.co – a journal and online resource reporting on business, economics and finance –...

Read more

Releases

4. March, 2021

Favourable data from the Registry Safety Study

First major milestone reached: Data from the Registry Safety Study (0203) indicates a favourable...

Read more

Releases

11. February, 2021

Year-end report Q4-2020 – on track and accelerating clinical activities

Cessatech A/S today releases its results for the period 6. April – 31 December 2020. The company is on track with Q4 activities and getting...

Read more

Facts

2. February, 2021

Ny forskning: Barn bör få smärtlindring vid vaccinationer och injektioner

Barn mår bra av smärtlindring vid vanliga vaccinationer och injektioner. Det säger den senaste...

Read more

Releases

21. January, 2021

Supporting ‘Save the Children’

Cessatech has entered a corporate sponsorship with Save the Children. We want to make...

Read more

Stay up to date!

Subscribe and get notified on Cessatech's latest news.
An acceptance email will be sent to you, please check your spam.